ZBIO

In January 2026, Zenas BioPharma reported positive Phase 3 clinical trial results for obexelimab in IgG4-Related Disease, showing a 56% reduction in flare risk, and the FDA accepted its Biologics License Application (BLA) in August 2026 with a PDUFA target action date of May 27, 2027, with an EMA Marketing Authorization Application anticipated in the second half of 2026. Despite these positive results, the stock experienced a 50% decline due to investor concerns over market competition and the company's long-term commercial viability, including a 'going concern' warning. In August 2026, the company reported a Q2 2026 net loss of $111.5 million, wider than the previous year, with revenue of $1.00 million, missing consensus estimates. Financing activities included a $250 million loan agreement in March 2026 and the filing of shelf registration statements in September 2026 for up to $244.69 million of common stock, which could lead to potential dilution. The company also announced inducement equity awards to newly hired employees in July and September 2026. As of October 2026, analysts have a 'Moderate Buy' consensus rating with an average price target of $46.71. The stock was up 59.2% over the 90 days leading up to October 6, 2026, but was down 15.4% year-to-date.